Skip to main content

RT @uptoTate: ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of

Social Author Name
Dr. Rachel Tate
Tweet Content
ATOM study, Abs 1314, greater proportion of men with OP on abaloparatide vs placebo met the definition of a >3% responder at the LS, TH, and FN. #ACR22 @RheumNow https://t.co/q6gcX5Azts https://t.co/WEjqbl14ZN

RT @AkhilSoodMD: #Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional

Social Author Name
Akhil Sood MD
Tweet Content
#Abstr 1609 - comorbidity clusters in pts with #AS and association w/ disease activity and functional impairment using PSOAS cohort - identified 5 clusters based on comorbidity - Depression cluster --> ↑ disease activity and fxnl impairment @RheumNow #ACR22 https://t.co/cGz4vpOGJ9

RT @uptoTate: Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and

Social Author Name
Dr. Rachel Tate
Tweet Content
Glucocorticoids ≤5 mg/d did not seem to be associated with a reduction of BMD in patients with iRMD and current or prior exposure to GC. Abs 1319 #ACR22 @RheumNow https://t.co/xbYW9y522I https://t.co/QQVjVXoFNf

RT @uptoTate: Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP

Social Author Name
Dr. Rachel Tate
Tweet Content
Abs 1307 at #ACR22 Romo did not negatively impact knee OA pain or function in postmenopausal women with OP. @RheumNow https://t.co/VMkUnwWt4v https://t.co/fTRPo25GZm

RT @uptoTate: PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR2

Social Author Name
Dr. Rachel Tate
Tweet Content
PC4d≥10 MFI is associated with thrombosis in SLE and predicts future arterial thrombosis. Abs 1442 #ACR22 @RheumNow https://t.co/zg7rrOSALs https://t.co/Hs2eOa2vxJ

RT @uptoTate: In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effect

Social Author Name
Dr. Rachel Tate
Tweet Content
In RA pts initiating their first b/tsDMARD, Abs 1420 did not observe differences in 6- and 12-month effectiveness outcomes between ETN, ADA, and JAKi monotherapy. #ACR22 @RheumNow https://t.co/e8GA45Rrmd https://t.co/zooGxlTftO

RT @uptoTate: Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @Rhe

Social Author Name
Dr. Rachel Tate
Tweet Content
Numerically, SLE was more common in cITP patients. Risks include +ANA and female sex. Abs 1461 #ACR22 @RheumNow https://t.co/0kyqlVphac https://t.co/HfYKCMybdL

RT @uptoTate: While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mor

Social Author Name
Dr. Rachel Tate
Tweet Content
While myositis in the setting of SLE was found to be around 5% in Abs 1453, it was not associated with mortality. #ACR22 @RheumNow https://t.co/hLLuYoXsCv https://t.co/44XGhbPxzW
ACR Best Abstracts - Day 2
Day two at ACR 2022 was full of great sessions on imaging, vasculitis, lupus, vasculitis, spondyloarthritis, COVID, pregnancy, microbiome, economics and more. Here are the RheumNow faculty selections for #ACRbest abstracts today:

RT @uptoTate: DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and acces

Social Author Name
Dr. Rachel Tate
Tweet Content
DAVIX is a promising surrogate outcome measure of vascular disease in SSc. Questions around cost and access remain. Abs 1541 #ACR22 @RheumNow https://t.co/KJgtcG5ah8 https://t.co/NsK7b8fQFt
Subscribe to
×